November 29, 2006 -- Dynavax reported very solid data for its hepatitis B vaccine Heplisav in older adults; Pfizer will cut its US sales force by 20%; the new abuse-resistant opioid painkiller from Pain Therapeutics was safe and well-tolerated; Threshold announced the delay of results from a trial of glufosfamide for pancreatic cancer; Dyax will collaborate with the national scientific research agency of Australia; Sangamo began a Phase II trial of SB-509 for diabetic neuropathy; Teva received tentative approval for a generic equivalent to Imitrex from GlaxoSmithKline; Arena Pharma slumped after indicating it would offer 8 million new shares; and Acorda received $10 million from Paul Capital to beef up its sales efforts. The Centient Biotech 200™ rose 43 points to 3982, a gain of 1.10%. More details...
